Protagenic Therapeutics granted new patent in Japan for modified stilbenoid
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 30 2025
0mins
Should l Buy ?
Patent Grant Announcement: Protagenic Therapeutics received a patent (JP 7714571B) from the Japanese Patent Office on July 18, 2025, which is valid until March 31, 2041, covering a modified stilbenoid for treating epilepsy and seizures.
Company's Future Plans: The COO of Protagenic expressed optimism about the patent's significance for the company's pipeline and indicated intentions to seek similar patents in other regions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
